Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for …
MÉ Plante, X Feng, JS Boudreault - Leukemia & Lymphoma, 2023 - Taylor & Francis
One of the most widely accepted conditioning regimens for hematopoietic stem cell
transplantation (HSCT) is BEAM (carmustine, etoposide, cytarabine, melphalan). However, a …
transplantation (HSCT) is BEAM (carmustine, etoposide, cytarabine, melphalan). However, a …
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience
K Saleh, A Danu, S Koscielny, C Legoupil… - Leukemia & …, 2018 - Taylor & Francis
The combination of carmustine, etoposide, aracytin, and melphalan (BEAM) conditioning
regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with …
regimen in autologous stem-cell transplantation (ASCT) is widely used in patients with …
Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning …
A Frankiewicz, M Saduś-Wojciechowska… - Contemporary …, 2018 - termedia.pl
Results Median time to neutrophil> 0.5× 109/l recovery was 10 days in both groups (p=
0.29), while median time to platelet> 50× 109/l recovery was 13 and 14 days after BEAM and …
0.29), while median time to platelet> 50× 109/l recovery was 13 and 14 days after BEAM and …
Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from LYmphoma Study …
SP Chantepie, S Garciaz, E Tchernonog… - American journal of …, 2018 - Wiley Online Library
Carmustine shortage has led to an increase use of alternative conditioning regimens prior to
autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine …
autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine …
BeEAM (bendamustine, etoposide, cytarabine, melphalan) versus BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning regimen before autologous …
R Wu, L Ma - Cell Transplantation, 2023 - journals.sagepub.com
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …
standard of care for selected patients with refractory/relapsed Hodgkin's lymphoma (HL) or …
[HTML][HTML] Bendamustine based conditioning regime (BACE-bendamustine, cytarabine, cyclophosphamide and etoposide) for patients with lymphoma undergoing …
N Jain, A Chakravarti, N Sood, A Arabandi… - Biology of Blood and …, 2016 - tctjournal.org
Background Autologous Stem Cell Transplantation (ASCT) is standard of care in relapsed
diffuse large B-cell lymphoma (DLBCL) and other lymphoproliferative disorders. Carmustine …
diffuse large B-cell lymphoma (DLBCL) and other lymphoproliferative disorders. Carmustine …
[HTML][HTML] Bendamustine-based (BeEAM) conditioning before autologous stem cell transplantation: result of a French multicenter study of 386 patients from Lysa …
S Chantepie, E Tchernonog, F Peyrade, MV Larcher… - Blood, 2016 - Elsevier
Unavailability of Carmustine and its dramatically increased cost by nearly 10 fold has led to
its replacement by bendamustine (Be) and an increase use of Bendamustine-based …
its replacement by bendamustine (Be) and an increase use of Bendamustine-based …
[HTML][HTML] A novel high dose chemotherapy strategy with bendamustine in adjunct to etoposide, cytarabine and melphalan (BeEAM) followed by autologous stem cell …
G Visani, L Malerba, PM Stefani, S Capria, P Galieni… - Blood, 2010 - Elsevier
Abstract Abstract 31 Background: BEAM (Carmustine, etoposide, cytarabine, and
melphalan) regimen is the most used conditioning regimen before autologous stem cell …
melphalan) regimen is the most used conditioning regimen before autologous stem cell …
Bendamustine-based conditioning regime (BACE-bendamustine, cytarabine, cyclophosphamide and etoposide) for patients with lymphoma undergoing autologous …
J Chakrabartty, N Jain, P Sarada… - Biology of Blood and …, 2017 - astctjournal.org
We have already shown that Bendamustine when replaced for Lomustine is an effective and
safe regime for autologous stem cell transplant for relapsed and refractory high grade …
safe regime for autologous stem cell transplant for relapsed and refractory high grade …
Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´ s Lymphoma
T Noesslinger, M Panny, M Moestl, E Koller, F Keil - 2016 - ashpublications.org
Abstract Autologous Stem Cell Transplantation (ASCT) is standard of care in relapsed
diffuse large B-cell lymphoma (DLBCL) and other lymphoproliferative disorders (relapsed …
diffuse large B-cell lymphoma (DLBCL) and other lymphoproliferative disorders (relapsed …